{"nctId":"NCT02093897","briefTitle":"Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A","startDateStruct":{"date":"2014-03"},"conditions":["Congenital Hemophilia A"],"count":84,"armGroups":[{"label":"rVIII-SingleChain","type":"EXPERIMENTAL","interventionNames":["Biological: rVIII-SingleChain"]}],"interventions":[{"name":"rVIII-SingleChain","otherNames":["Recombinant Factor VIII single chain","CSL627"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of severe hemophilia A defined as \\< 1% Factor VIII (FVIII) concentration (FVIII:C) documented in medical records,\n* Males \\< 12 years of age,\n* Subjects who have received \\> 50 EDs with a FVIII product,\n* Prior PK data (at least incremental recovery and half-life) from previous FVIII exposure for subjects participating in the PK part\n* Investigator believes that the subject is willing and able to adhere to all protocol requirements. Investigator believes that the subject's parent(s) or legally acceptable representative(s) is / are willing and able to adhere to all protocol requirements.\n\nExclusion Criteria:\n\n* Any history of or current FVIII inhibitors\n* Use of an Investigational Medical Product (IMP) within 30 days prior to the first rVIII-SingleChain administration,\n* Administration of any cryoprecipitate, whole blood or plasma within 30 days prior to administration of rVIII-SingleChain,\n* Known hypersensitivity (allergic reaction or anaphylaxis) to any FVIII product or hamster protein,\n* Subject currently receiving IV immunomodulating agents such as immunoglobulin or chronic systemic corticosteroid treatment,\n* Subject with serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) values \\>5 times (x) the upper limit of normal (ULN) at Screening,\n* Subjects with serum creatinine values \\>2 x ULN at Screening,\n* Evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction and arterial embolus within 3 months before Day 1,\n* Experienced life-threatening bleeding episode or had major surgery or an orthopedic surgical procedure during the 3 months before rVIII-SingleChain administration.","healthyVolunteers":false,"sex":"MALE","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment Success","description":"Rate of treatment success where treatment success of a bleeding episode is defined as a rating of \"excellent\" or \"good\" based on the investigator's overall clinical assessment of hemostatic efficacy (using a 4-point scale of excellent, good, moderate or poor/no response) on the on-demand and prophylaxis regimens combined. The rate of success was based on the number of treated bleeding events; there were 347 treated bleeding events in the Efficacy Population.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Bleeding Rate","description":"The annualized bleeding rate was defined as the number of bleeding episodes requiring treatment divided by the efficacy evaluation period in days, x 365.25, and is presented separately for the on-demand regimen and the prophylaxis regimens.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.56","spread":null},{"groupId":"OG001","value":"3.69","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Bleeding Episodes Requiring 1, 2, 3, or More Than 3 Infusions of rVIII-SingleChain to Achieve Hemostasis.","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Consumption of rVIII-SingleChain - IU/kg Per Subject Per Month","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"202","spread":null},{"groupId":"OG001","value":"378","spread":null}]}]}]},{"type":"SECONDARY","title":"Consumption of rVIII-SingleChain - IU/kg Per Subject Per Year","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2429","spread":null},{"groupId":"OG001","value":"4541","spread":null}]}]}]},{"type":"SECONDARY","title":"Consumption of rVIII-SingleChain - IU/kg Per Bleeding Event","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.9","spread":null},{"groupId":"OG001","value":"37.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Consumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Month","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.58","spread":null}]}]}]},{"type":"SECONDARY","title":"Consumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Year","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Incremental Recovery","description":"Incremental recovery expressed as (IU/dL)/(IU/kg) corrected for subject's predose plasma FVIII activity measured using the chromogenic substrate assay.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.63","spread":"0.329"}]}]}]},{"type":"SECONDARY","title":"Half-life (t1/2) of rVIII-SingleChain","description":"Half-life (t1/2) of rVIII-SingleChain, baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"2.51"}]}]}]},{"type":"SECONDARY","title":"Area Under the Concentration Curve (AUC)","description":"AUC to the last sample with quantifiable drug concentration (AUC0-t), baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1050","spread":"286"}]}]}]},{"type":"SECONDARY","title":"Clearance (Cl) of rVIII-SingleChain","description":"Clearance (Cl) of rVIII-SingleChain, baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.86","spread":"1.43"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Inhibitor Formation to rVIII-SingleChain","description":"The number of subjects who develop inhibitors to rVIII-SingleChain, defined as a rVIII-SingleChain antibody titer of at least 0.6 Bethesda Units (BU) per mL after receiving study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":84},"commonTop":["Nasopharyngitis","Arthralgia","Cough","Headache","Head injury"]}}}